RNXT – renovorx, inc. (US:NASDAQ)
Stock Stats
News
RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET
RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting [Yahoo! Finance]
RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting
Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting
RenovoRx (RNXT) had its price target raised by Ascendiant Capital Markets from $13.00 to $13.50. They now have a "buy" rating on the stock.
Form EFFECT RenovoRx, Inc.
Form 424B3 RenovoRx, Inc.
Form SCHEDULE 13G/A RenovoRx, Inc. Filed by: HIRSCHMAN ORIN
Form S-3 RenovoRx, Inc.
Form D RenovoRx, Inc.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.